Clinical Trial Update: Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing GZR18 every two weeks to tirzepatide and placebo in adults who are obese or overweight, assessing efficacy and safety. The study is no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• GZR18
• Tirzepatide (tirzepatide)

Snippet

Sponsor: Gan and Lee Pharmaceuticals, USA | Conditions: Obesity and Overweight | Phase 2 | Status: NOT_YET_RECRUITING